Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 4/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 6/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.48 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30178579 | 0.83 | CNR1 (0.51) | CDK9CCNT1NAMPTCNR1TBK1 | |
| SCHEMBL31017627 | 0.82 | CNR1 (0.48) | CDK9CCNT1NAMPTCNR1TBK1 | |
| SCHEMBL25036987 | 0.82 | CNR1 (0.54) | CDK9CCNT1NAMPTCNR1TBK1 | |
| SCHEMBL30484043 | 0.82 | CNR1 (0.48) | CDK9CCNT1NAMPTCNR1TBK1 | |
| SCHEMBL30273978 | 0.82 | CNR1 (0.54) | CDK9CCNT1NAMPTCNR1TBK1 | |
| SCHEMBL29760339 | 0.81 | GRM1 (0.49) | CDK9CCNT1NAMPTCNR1TBK1 | |
| SCHEMBL23165947 | 0.81 | GRM1 (0.49) | CDK9CCNT1NAMPTCNR1TBK1 | |
| SCHEMBL23580367 | 0.80 | NAMPT (0.47) | CDK9CCNT1NAMPTCNR1GRM5 | |
| SCHEMBL30178737 | 0.80 | NAMPT (0.47) | CDK9CCNT1NAMPTCNR1GRM5 | |
| SCHEMBL26312619 | 0.80 | NAMPT (0.52) | CDK9CCNT1NAMPTCNR1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | CDK9 1717/4885CCNT1 3967/4885NAMPT 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.